XML 47 R6.htm IDEA: XBRL DOCUMENT v2.4.0.6
Consolidated Statements of Cash Flows (USD $)
12 Months Ended
Dec. 31, 2012
Dec. 31, 2011
Dec. 31, 2010
Operating activities:      
Net loss $ (14,939,000) $ (8,333,000) $ (6,038,000)
Adjustments to reconcile net loss to net cash provided by operating activities:      
(Gain) loss on interest rate swap (225,000) (328,000) 42,000
Depreciation and amortization 58,551,000 47,439,000 19,505,000
Amortization of deferred rent (82,000) (450,000) (61,000)
Share-based compensation 13,756,000 7,834,000 1,816,000
Excess tax benefit related to share-based compensation (2,853,000)   (974,000)
Provision for doubtful accounts 2,852,000 2,297,000 173,000
Amortization of deferred financing costs 2,190,000 1,941,000 872,000
Deferred income taxes (21,201,000) (6,364,000) (5,406,000)
Loss on early extinguishment of debt   621,000 3,169,000
Other (31,000)    
Changes in operating assets and liabilities, net of effects of acquisitions:      
Accounts receivable (24,666,000) (9,047,000) (2,098,000)
Prepaid expenses and other current assets (64,000) (1,801,000) 560,000
Accounts payable and accrued expenses 8,300,000 (1,907,000) 5,946,000
Accrued interest expense 671,000 10,240,000  
Deferred revenue and customer deposits 2,425,000 (169,000) (917,000)
Other liabilities 93,000 (2,430,000) 1,714,000
Net cash provided by operating activities 24,777,000 39,543,000 18,303,000
Investing activities:      
Cash paid for acquisitions, net (108,970,000) (322,248,000) (115,225,000)
Purchases of equipment and leasehold improvements, net (5,841,000) (6,856,000) (1,730,000)
Working capital and other settlements for acquisitions 427,000 (6,710,000) 418,000
Net cash used in investing activities (114,384,000) (335,814,000) (116,537,000)
Financing activities:      
Borrowings under credit facilities 170,640,000 278,000,000 67,315,000
Excess tax benefit related to share-based compensation 2,853,000   974,000
Proceeds from the exercise of options and warrants 2,258,000 2,292,000 703,000
Borrowings under senior unsecured notes payable   250,000,000  
Issuance of preferred stock, net     32,421,000
Issuance of common stock, net     136,660,000
Repayment of related party notes     (3,500,000)
Purchases of stock for treasury (387,000) (9,421,000)  
Payment of deferred financing costs (1,074,000) (9,746,000) (6,534,000)
Repayment of subordinated unsecured notes payable (2,193,000) (2,421,000) (2,167,000)
Net borrowings (repayments) under working capital facilities (6,279,000) 35,621,000 4,997,000
Repayment under credit facilities (76,000,000) (273,000,000) (100,550,000)
Other (94,000) (440,000)  
Net cash provided by financing activities 89,724,000 270,885,000 130,319,000
Exchange rate impact on cash and cash equivalents 94,000 178,000 40,000
Net increase (decrease) in cash and cash equivalents 211,000 (25,208,000) 32,125,000
Cash and cash equivalents, beginning of year 8,416,000 33,624,000 1,499,000
Cash and cash equivalents, end of year 8,627,000 8,416,000 33,624,000
Supplemental disclosure of noncash investing and financing activities:      
Issuance of subordinated unsecured notes payable for acquisitions     1,747,000
Issuance of common stock to settle earnout obligations   808,000 576,000
Issuance of common stock for termination of agreement     1,434,000
Supplemental disclosures of cash flow information:      
Cash paid for interest 25,214,000 5,447,000 4,994,000
Cash paid for income taxes 8,913,000 4,061,000 231,000
Issuance Of Common Stock For Acquisitions [Member]
     
Supplemental disclosure of noncash investing and financing activities:      
Issuance of common stock for acquisitions $ 85,000 $ 47,174,000 $ 10,075,000